A detailed history of Morgan Stanley transactions in Alvotech stock. As of the latest transaction made, Morgan Stanley holds 1,739,340 shares of ALVO stock, worth $20.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,739,340
Previous 58,291 2883.89%
Holding current value
$20.7 Million
Previous $708,000 2823.45%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.76 - $12.99 $18.1 Million - $21.8 Million
1,681,049 Added 2883.89%
1,739,340 $20.7 Million
Q2 2024

Oct 17, 2024

SELL
$11.4 - $14.51 $8.75 Million - $11.1 Million
-767,310 Reduced 92.94%
58,291 $708,000
Q2 2024

Aug 14, 2024

SELL
$11.4 - $14.51 $8.75 Million - $11.1 Million
-767,310 Reduced 92.94%
58,291 $708,000
Q1 2024

Oct 17, 2024

BUY
$11.36 - $17.27 $8.72 Million - $13.3 Million
767,310 Added 1316.34%
825,601 $10.1 Million
Q1 2024

Aug 16, 2024

BUY
$11.36 - $17.27 $9.38 Million - $14.3 Million
825,575 Added 3175288.5%
825,601 $10.1 Million
Q1 2024

May 15, 2024

BUY
$11.36 - $17.27 $9.38 Million - $14.3 Million
825,575 Added 3175288.5%
825,601 $10.1 Million
Q4 2023

Aug 16, 2024

SELL
$8.55 - $11.48 $498,165 - $668,882
-58,265 Reduced 99.96%
26 $0
Q4 2023

Feb 13, 2024

BUY
$8.55 - $11.48 $213 - $287
25 Added 2500.0%
26 $0
Q3 2023

Nov 15, 2023

BUY
$8.12 - $10.07 $8 - $10
1 New
1 $0
Q1 2023

May 15, 2023

SELL
$10.01 - $14.03 $10.4 Million - $14.6 Million
-1,038,727 Reduced 99.89%
1,193 $15,000
Q3 2022

Nov 14, 2022

BUY
$0.73 - $9.55 $757,833 - $9.91 Million
1,038,128 Added 57931.25%
1,039,920 $7.03 Million
Q2 2022

Aug 15, 2022

BUY
$8.21 - $11.19 $14,712 - $20,052
1,792 New
1,792 $15,000

Others Institutions Holding ALVO

About Alvotech


  • Ticker ALVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 248,650,000
  • Market Cap $2.96B
  • Description
  • Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...
More about ALVO
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.